Prognostic Impact of p53, p27, and C-MYC on Clinicopathological Features and Outcome in Early-Stage (FIGO I–II) Epithelial Ovarian Cancer

Skírnisdóttir, Ingiridur; Sorbe, Bengt; Lindborg, Katarina; Seidal, Tomas

doi:10.1097/igc.0b013e31820986e5

Cited by 23 publications

(28 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, numerous recent analyses also confirmed its role in 205 (Lee et al 2011), 131 (Skirnisdottir et al 2011), and339 (Duncan et al 2010) patients. p27 is measured by only one probe set on the microarrays, and this probe set delivered high prognostic power in our analysis.…”

Section: B Győ Rffy Et Al: Survival Analysis In Ovarian Cancermentioning

confidence: 70%

Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients

Győrffy¹,

Lánczky²,

Szállási³

2012

Endocrine-Related Cancer

788

824

View full text Add to dashboard Cite

The validation of prognostic biomarkers in large independent patient cohorts is a major bottleneck in ovarian cancer research. We implemented an online tool to assess the prognostic value of the expression levels of all microarray-quantified genes in ovarian cancer patients. First, a database was set up using gene expression data and survival information of 1287 ovarian cancer patients downloaded from Gene Expression Omnibus and The Cancer Genome Atlas (Affymetrix HG-U133A, HG-U133A 2.0, and HG-U133 Plus 2.0 microarrays). After quality control and normalization, only probes present on all three Affymetrix platforms were retained (nZ22 277). To analyze the prognostic value of the selected gene, we divided the patients into two groups according to various quantile expressions of the gene. These groups were then compared using progression-free survival (nZ1090) or overall survival (nZ1287). A Kaplan-Meier survival plot was generated and significance was computed. The tool can be accessed online at www.kmplot. com/ovar. We used this integrative data analysis tool to validate the prognostic power of 37 biomarkers identified in the literature. Of these, CA125 (MUC16; PZ3.7!10 K5

show abstract

Section: B Győ Rffy Et Al: Survival Analysis In Ovarian Cancermentioning

confidence: 70%

Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients

Győrffy¹,

Lánczky²,

Szállási³

2012

Endocrine-Related Cancer

788

824

View full text Add to dashboard Cite

show abstract

“…In cases of histologic cell type, it is the predominant conclusion that the results of related references [15,16,21] shows insignificant HR in RFS, and thus this paper concluded that the influence of histologic cell type recurrence on early-stage EOC was not significant.…”

Section: Meta-analysismentioning

confidence: 59%

“…Among them, two [17,18] substantially overlapped in study organization and period, but there was no overlap in the description of the results, so both were enrolled in the present study. Some of the studies were RCTs [13,14,[16][17][18][19] and some were observational studies [15,[20][21][22]. The methodological qualities and the results of the studies included in this meta-analysis are summarized in Table 1.…”

Section: Meta-analysismentioning

confidence: 99%

A new prognostic index model using meta-analysis in early-stage epithelial ovarian cancer

Park

Nam

Rha

et al. 2012

Gynecologic Oncology

View full text Add to dashboard Cite

“…This study assessed 105 patients in FIGO-stages I-II epithelial ovarian cancer, who were a part of a patient population of 131 patients in earlier published studies (18,19). The study was approved by the local Ethics Committee (decision ref.…”

Section: Methodsmentioning

confidence: 99%

The apoptosis regulators p53, bax and PUMA: Relationship and impact on outcome in early stage (FIGO I-II) ovarian carcinoma after post-surgical taxane-based treatmen

Skírnisdóttir

Seidal²

2011

Oncol Rep

View full text Add to dashboard Cite

Abstract. The objective of this study was to evaluate the prognostic effect of the apoptosis regulators p53, bax and PUMA for recurrent disease and disease-free survival (DFS) in a series of 105 patients in FIGO-stages I-II with epithelial ovarian cancer, all treated with post-surgical platinum-taxane chemotherapy. For the detection of positivity of the biological markers p53, bax and PUMA the techniques of tissue microarrays and immunohistochemistry (IHC) were used. In tumors the frequency of p53 positivity was 24%, that of bax positivity was 83%, and strong positivity was found for PUMA (43%). The bax status was related to tumor grade (P=0.029). Positive staining for bax was related to strong positivity of PUMA in the tumors (P=0.004). The p53, bax or PUMA status alone or concomitant (p53 bax, p53 PUMA and bax PUMA) were not related to age, histopathological subtype, serous/non-serous tumors or type of the staging procedure at primary surgery. In survival analysis p53-positive tumors (P=0.014) and concomitant p53-positive and weak PUMA-positive tumors (P=0.015) were significantly correlated with shorter DFS. Concomitant p53-negative and bax-positive tumors were significantly correlated with longer survival (P=0.019). FIGO-stage (OR=6.0) and p53 status (OR=4.1) were predictive factors for tumor recurrence in logistic regression analysis and independent prognostic factors (HR=2.4 for both) in multivariate Cox regression analysis. In a separate Cox multivariate regression analysis the p53 bax status (HR=2.2) was an independent prognostic factor for DFS. The p53 PUMA status (HR=0.4) was not an independent prognostic factor, however, a borderline significance (P=0.07) was noted. Our results indicate that FIGO stage and p53 status alone were independent predictive factors for recurrence and prognostic factors for survival.Furthermore, p53 bax status was an independent prognostic factor for survival in this study.

show abstract

Prognostic Impact of p53, p27, and C-MYC on Clinicopathological Features and Outcome in Early-Stage (FIGO I–II) Epithelial Ovarian Cancer

Cited by 23 publications

References 32 publications

Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients

Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients

A new prognostic index model using meta-analysis in early-stage epithelial ovarian cancer

The apoptosis regulators p53, bax and PUMA: Relationship and impact on outcome in early stage (FIGO I-II) ovarian carcinoma after post-surgical taxane-based treatmen

Contact Info

Product

Resources

About